Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – Yahoo…
By daniellenierenberg
Co-founded by World-Renowned Stem Cell Scientist Jeanne F. Loring, Ph.D. and Andres Bratt-Leal, Ph.D.
Led by Chief Executive Officer Howard Federoff, M.D., Ph.D., Former Vice Chancellor for Health Affairs and Chief Executive Officer of the University of California Irvine Health System
SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments,Arch Venture Partners,OrbiMedand Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.
Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinsons disease. Aspens therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement.
Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.
As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.
Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.
Story continues
Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.
Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.
"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."
Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.
"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."
About Aspen Neuroscience
Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease-300973830.html
SOURCE Aspen Neuroscience
Read the original here:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - Yahoo...
- Much-anticipated human trial aiming to repair spinal cord damage about to begin - ABC News - October 21st, 2024
- The Science Of Health: Are Spinal Cord Injuries Irreversible? Know Science Advances That Can Cure Them In The Future - ABP Live - October 16th, 2023
- Evaluating the Growth Prospects of the Global Nerve Repair & Regeneration Market at a CAGR of 6.5% | Emergen - EIN News - April 21st, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 17th, 2023
- Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx for the Treatment of ALS - Marketscreener.com - February 21st, 2023
- My Back Is All F*cked Up 55-Year-Old Joe Rogan Curses at Worst Jiu-Jitsu for Painful Health Condition - EssentiallySports - February 21st, 2023
- Brain and Spinal Cord Tumors: Hope Through Research - January 3rd, 2023
- 14.3 The Brain and Spinal Cord Anatomy & Physiology - January 3rd, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - January 3rd, 2023
- Spinal cord injury - Diagnosis and treatment - Mayo Clinic - December 25th, 2022
- Spinal Cord Injury: Hope Through Research | National Institute of ... - December 1st, 2022
- Stem cell controversy - Wikipedia - October 13th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 13th, 2022
- The eye and stem cells: the path to treating blindness - October 13th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology - Yahoo Finance - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Horizon Therapeutics plc Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS... - October 13th, 2022
- Physiology, Spinal Cord - StatPearls - NCBI Bookshelf - October 5th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 ... - October 5th, 2022
- Revolutionary Jab that Could Repair Spinal Cord Injuries Developed by Scientists - Good News Network - October 5th, 2022
- How the 'Love Hormone' Oxytocin May Help Heal Heart Muscles - Healthline - October 5th, 2022
- Unlocking the Mysteries of Brain Regeneration Groundbreaking Study Offers New Insight - SciTechDaily - October 5th, 2022
- In Conversation: How to understand chronic pain - Medical News Today - October 5th, 2022
- New drug could cure aggressive brain cancer stopping tumours in their tracks... - The US Sun - September 27th, 2022
- Rehabilitating spinal cord injury and stroke with graphene and gaming - Nanowerk - September 19th, 2022
- Induced Pluripotent Stem Cells Market Reaches at a CAGR of 8.0% in the Forecast Periods [2021-2031] - BioSpace - September 19th, 2022
- Axolotls can regenerate their brains - Big Think - September 19th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the... - September 11th, 2022
- Spinal Muscular Atrophy: Causes and importance of early diagnosis for proactive management - Firstpost - September 11th, 2022
- Increasing Road Accidents and Fall Injuries among Aged Population Primarily Driving Need for Orthopedic Navigation Systems: Fact.MR Analysis - Yahoo... - September 3rd, 2022
- Culture of human nasal olfactory stem cells and their extracellular vesicles as advanced therapy medicinal products - Newswise - August 10th, 2022
- Curious kids: what is inside teeth? - The Conversation - August 10th, 2022
- Human placental mesenchymal stem cells derived exosomes improved functional recovery via attenuating apoptosis and increasing axonal regeneration... - August 2nd, 2022
- How the Regenerative Properties of Glioblastoma Can Be Terminated - Gilmore Health News - August 2nd, 2022
- New TSXV listing looks to address the $3B spinal cord injury treatment market (NRX.V) - FXStreet - July 25th, 2022
- Human iPSC co-culture model to investigate the interaction between microglia and motor neurons | Scientific Reports - Nature.com - July 25th, 2022
- Negligence in treatment of diseases like glioblastoma can be fatal, seminar told - The News International - July 25th, 2022
- What lab-grown cerebral organoids are revealing about the brain - New Scientist - July 25th, 2022
- Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting - Targeted Oncology - July 16th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 16th, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - June 30th, 2022
- This startup wants you to have a personal stem cell stash - Freethink - June 30th, 2022
- Parents of 12-Year-Old Boy Praying for a Miracle, Appealing UK Judge's Decision to Remove Life Support - CBN.com - June 30th, 2022
- The end of Roe v. Wade affects more than just abortion - Vox.com - June 30th, 2022
- Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA (inebilizumab) in Brazil - Business Wire - June 20th, 2022
- Effect of Electrical Stimulation on Spinal Cord Injury: In Vitro and In Vivo Analysis - Newswise - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UK Judge to Decide if 12-Year-Old Will Be Removed from Life Support, Parents Beg for More Time to Heal - CBN.com - June 11th, 2022
- 'This is my life, and I'll try anything to save it': Woman with MS raising funds for treatment - The Brandon Sun - May 29th, 2022
- Racing Thoughts: Quadriplegic Man Drives Race Car With His Brain - Newsy - May 29th, 2022
- Physical therapy for vertigo: Exercises, benefits, and more - Medical News Today - May 29th, 2022
- Researchers find new function performed by almost half of brain cells - Medical News Today - May 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 13th, 2022
- Severe COVID-19 may cause cognitive deficits equivalent to 20 years of aging - Medical News Today - May 13th, 2022
- Stem Cell Magic: 5 Promising Treatments For Major Medical Conditions - Study Finds - April 29th, 2022
- Neural Stem Cell Therapy For Spinal Cord Injury To Tap Into The Potential Of Stem Cells - Optic Flux - April 15th, 2022
- Still Blooming: Sams mission to raise money for spinal cord injury research - 7NEWS - April 15th, 2022
- Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung... - April 15th, 2022
- Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss - Galveston County Daily News - March 22nd, 2022
- COVID-19: Even mild to moderate infection may cause brain anomalies - Medical News Today - March 22nd, 2022
- Scots mum with MS says 50k treatment abroad is 'last hope' of halting disease - Daily Record - January 18th, 2022
- Mending the gap: U of T's Molly Shoichet joins team developing new treatments for spinal cord injuries - News@UofT - January 18th, 2022
- Spinal Cord Injury Information Page | National Institute ... - January 3rd, 2022
- Dancing molecules successfully repair severe spinal cord ... - January 3rd, 2022
- Best 2021 Medical Breakthroughs And Treatments to Beat Cancer, Alzheimer's, Diabetes & More - Good News Network - January 3rd, 2022
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Scientists unravel a gene function that helps the genesis of neurons - Research Matters - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- 2021: The year in review | YaleNews - Yale News - December 23rd, 2021
- Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire - December 10th, 2021
- Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen... - November 8th, 2021
- Akiko Nishiyama Explains the Many Strengths of a Degree in Physiology and Neurobiology - UConn Today - UConn Today - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- 'Rogue' antibodies found in brains of teens with delusions and paranoia after COVID-19 - Livescience.com - October 28th, 2021
- Traumatic Spinal Cord Injury: An Overview of ... - October 16th, 2021
- Role of Stem Cells in Treatment of Neurological Disorder - October 16th, 2021